September 17th 2024
Patients with at least 1 NE-positive marker were shown to have a worsened rPFS and OS.
September 16th 2024
FDA grants priority review to olaparib/abiraterone combo for mCRPC
August 16th 2022The application is supported by the phase 3 PROpel trial, which showed that adding olaparib to frontline abiraterone acetate and prednisone/prednisolone significantly improved radiographic progression-free survival in patients with mCRPC.
Do 5-ARIs protect against death from prostate cancer?
August 12th 2022"It is evident...that the safety of 5-ARIs as it relates to prostate cancer outcomes is contingent upon the clinician understanding its effect on PSA level and making appropriate adjustments to ensure timely deployment of diagnostic imaging and biopsy," writes Badar M. Mian, MD.
The effects of exercise before and after a prostate cancer diagnosis
August 11th 2022"This article serves as a summary of the literature published in the past 3 years, documenting the impact of exercise and physical activity on prostate cancer development and on cancer-specific, treatment-related, and patient-reported outcomes," writes Christine Ibilibor, MD, MSc.
Available Monotherapies and Combination Therapies in mCSPC
August 9th 2022An expert provides an overview of the types of androgen deprivation therapy (ADT) for mCSPC, other therapies that can be used in combination with ADT for treatment intensification and compares the safety and efficacy of the various regimens.
Prostate Cancer Staging, Incidence of Clinically Localized Disease, and Patient Risk Stratification
August 8th 2022A prostate cancer specialist breaks down prostate cancer staging and grading and identifies several shortcomings of established risk stratification methods for patients with clinically localized disease.
The Diagnostic Journey of Prostate Cancer: Common Tests and Procedures Used in the US and UK
August 8th 2022Mark Emberton, BSc, MBBS, FRSC (Urol), MD, FMedSci describes his approach to diagnosing patients with prostate cancer, highlighting prostate-specific antigen (PSA) testing and magnetic resonance imaging (MRI) as critical to cancer detection.